Bayer's Courtroom Wins and China Approvals Don't Yet Fix a Cash Drain

Bayer shareholders are being asked to hold two ideas in their heads at once. The operating business is genuinely improving, and the legal and regulatory news has been broadly favourable. Yet the group still expects to burn cash this year, and the largest single legal question hanging over it has not been settled.

That tension explains why the stock's moves this week have been modest relative to the volume of headlines. Shares added 4.5% as investors digested Tuesday's quarterly release and the raised full-year guidance, with a separate 3.0% advance accompanying the mixed picture of business progress and unresolved litigation.

The numbers behind the optimism

Tuesday's third-quarter report for 2026 showed revenue of EUR 10.053 billion, a reported increase of 4.1%. EBITDA before special items came in at EUR 1.615 billion, up 6.9% on the quarter. Management pointed to the strength of the pharmaceuticals division as the main driver — a detail that matters because it means the improved outlook rests on trading performance rather than the hope of legal relief.

On the back of those figures, Bayer lifted its full-year guidance for EBITDA before special items, at constant currencies, to EUR 9.8–10.3 billion.

Analysts moved quickly. James Quigley of Goldman Sachs raised his price target to EUR 66.00 from EUR 63.50 and reiterated his buy rating, according to media reports. Matthew Weston at UBS had already lifted his own target on Tuesday while keeping a buy recommendation, and both houses now sit at EUR 66. These are estimates, not guarantees, and the confidence behind them will need to be validated by results.

A mixed week in the courts

The litigation picture is where the story gets more complicated, and where precision matters. On 30 October, a Missouri jury ruled unanimously in Monsanto's favour, dismissing claims relating to product design, fraud and negligence in a case involving three plaintiffs. A day earlier, on 29 October, all jurors in the first glyphosate trial since the US Supreme Court's ruling sided with Monsanto; according to Bayer, the plaintiffs could not prove their claims.

Both are completed outcomes in individual cases. Neither closes the book on glyphosate risk as a whole.

Separately, the proposed Roundup settlement of USD 7.25 billion is still under review by a Missouri court. CEO Bill Anderson said this week, according to media reports, that Bayer expects a decision before Christmas. A pending review is not the same as an approval, and investors should not treat the two as interchangeable.

China opens a second front

The regulatory news has been more clear-cut. Bayer announced Chinese first-line approval for Sevabertinib in adults with advanced HER2-mutated non-small cell lung cancer, based on data from the ongoing Phase I/II SOHO-01 study. That is a regulatory decision in hand, not a review still to come — but it establishes a treatment pathway, not a revenue line.

A second Chinese green light arrived on 26 October for Asundexian, covering the reduction of stroke risk in adults after non-cardioembolic ischaemic stroke or high-risk TIA. The two approvals address different therapeutic areas, which gives Bayer more than one shot at building a broader pharmaceutical base. Neither, on its own, translates into a specific earnings contribution.

The balance sheet is the counterweight

Set against all of this is the cash position. Bayer expects free cash flow of minus EUR 1.5 billion to minus EUR 0.5 billion for the current financial year — the improved guidance still envisages an outflow. Net financial debt at year-end is projected at EUR 28.0–29.0 billion.

Higher operating profit and fresh approvals do not automatically solve that. The quality of the improvement is what counts: a stronger result would carry more weight if it showed up in liquidity too. If it does not, the financial position could cap the valuation despite the medical progress.

What to watch next

Bayer plans to present new data on cardiovascular disease, kidney conditions and stroke at the scientific sessions of the American Heart Association 2026. For investors these carry a different function from quarterly figures: they can sharpen the medical outlook, but they do not substitute for evidence of commercial returns.

The bull case holds together as long as Bayer sustains the upgraded earnings guidance and converts its pharmaceutical progress into money. Should the earnings base weaken, or liquidity lag the improved target, that thesis would lose its force. The courtroom wins and the China approvals are real. What remains open is whether they add up to a durable earnings foundation — and whether the cash drain reverses before the legal questions are finally put to rest.